Results 111 to 120 of about 2,243,647 (283)

Spatiotemporally Controlled Sequential Chemo‐Immunotherapy Activates Pyroptosis for Robust Anti‐Tumor Immunotherapy

Advanced Science, EarlyView.
A glutathione and ultrasound dual‐responsive cerasome achieves sequential co‐delivery of gemcitabine and BMS1166 in tumors. Chemotherapy priming followed by on‐demand PD‐L1 blockade synergistically amplifies anti‐tumor immunity, inhibiting primary tumor growth, distant metastasis and inducing durable immune memory.
Suhui Sun, Ruiqi Wu, Qingshuang Tang, Yunli Xu, Wanrui Shi, Mengxin Wang, Haonan Wang, Yan Luo, Cheng Ma, Xiaolong Liang   +9 more
wiley   +1 more source

A Metabolic‐Epigenetic Axis of AARS1/IGF2BP3‐K280 Lactylation Sustains Endometrial Cancer Stemness and Recurrence

Advanced Science, EarlyView.
Lactate‐driven endometrial cancer relapse is mediated by enzymatic protein modification. Elevated lactate levels activate AARS1, which catalyzes K280 lactylation of IGF2BP3, therefore stabilizing HMGA2 mRNA and promoting tumor stemness and recurrence.
Peng Jiang, Yunfeng Zheng, Chenfan Tian, Yuan Tu, Xiaoxia Chang, Jiaxin Yu, Hangkun Yu, Chunxia Gong, Jie Xiong, Philip N. Baker, Yong Fu, Chao Tong   +11 more
wiley   +1 more source

Effect of midkine on gemcitabine resistance in biliary tract cancer

International Journal of Molecular Medicine, 2018
Gemcitabine‑based chemotherapy is one of the most effective and commonly used chemotherapeutic regimens for biliary tract cancer (BTC). However, development of resistance to this drug limits its efficacy. The present study aimed to explore the effects of midkine (MDK) on the resistance of BTC cells to gemcitabine.
Lu, Yongliang, Yan, Bing, Guo, Huihui, Qiu, Li, Sun, Xinrong, Wang, Xiang, Shi, Qian, Bao, Ying   +7 more
openaire   +3 more sources

Impact of Histopathological Response on Outcomes After Surgical Resection Following Carbon‐Ion Radiotherapy for Pancreatic Cancer With Arterial Involvement

Annals of Gastroenterological Surgery, EarlyView.
ABSTRACT Aim Carbon‐ion radiotherapy (CIRT) provides superior dose distribution and higher biological effectiveness than conventional X‐ray radiotherapy and has emerged as a promising component of multidisciplinary treatment for advanced pancreatic ductal adenocarcinoma (PDAC).
Kenichiro Araki, Norio Kubo, Yuhei Miyasaka, Hayato Ikota, Ryo Muranushi, Mariko Tsukagoshi, Takamichi Igarashi, Masahiko Okamoto, Tatsuya Ohno, Ken Shirabe   +9 more
wiley   +1 more source

Supranational surveillance of antimicrobial resistance: The legacy of the last decade and proposals for the future

, 2010
Antimicrobial resistance among clinically important bacteria is widely acknowledged as a major global public health threat. A decade ago, several supranational surveillance initiatives were introduced. Few of them are still ongoing, and only one features
CORNAGLIA, Giuseppe, Giske CG, European Study Group on Antimicrobial Resistance Surveillance   +2 more
core   +1 more source

ERCC1 expression and RAD51B activity correlate with cell cycle response to platinum drug treatment not DNA repair [PDF]

, 2008
Background: The H69CIS200 and H69OX400 cell lines are novel models of low-level platinum-drug resistance. Resistance was not associated with increased cellular glutathione or decreased accumulation of platinum, rather the resistant cell lines have a cell
Davey, Ross, Stordal, Britta, Stordal, B., Davey, R.   +3 more
core   +2 more sources

Zebrafish xenograft models as a fast platform for metastasis diagnosis and cisplatin response of head and neck squamous cell carcinoma

Animal Models and Experimental Medicine, EarlyView.
A zebrafish xenograft model accurately distinguishes metastatic from non‐metastatic HNSCC and recapitulates cisplatin sensitivity/resistance patterns. Using patient‐derived tumors, it predicts individual therapeutic responses, offering a rapid, clinically applicable platform for guiding personalized treatment. Abstract Background Head and neck squamous
Lu Chen, Shu Sun, Yujia Liu, Liehao Jiang, Cuiyun Wu, Ting Liu, Yujiao Zhao, Yuwei Liu, Lu Liu, Qi Wang, Xiaowei Zheng, Ping Huang   +11 more
wiley   +1 more source

Safety and efficacy of combination therapy with low-dose gemcitabine, paclitaxel, and sorafenib in patients with cisplatin-resistant urothelial cancer [PDF]

, 2015
Various regimens including molecular targeted agents have been examined in patients with cisplatin (CDDP)-resistant urothelial cancer (UC). However, some studies have been stopped owing to the development of severe adverse events.
Matsuo, Tomohiro, Ohba, Kojiro, Mitsunari, Kensuke, Asai, Akihiro, Miyata, Yasuyoshi, Sakai, Hideki   +5 more
core   +1 more source

Potential Development of Tumor-Targeted Oral Anti-Cancer Prodrugs: Amino Acid and Dipeptide Monoester Prodrugs of Gemcitabine

Molecules, 2017
One of the main obstacles for cancer therapies is to deliver medicines effectively to target sites. Since stroma cells are developed around tumors, chemotherapeutic agents have to go through stroma cells in order to reach tumors.
Yasuhiro Tsume, Adam J. Drelich, David E. Smith, Gordon L. Amidon   +3 more
doaj   +1 more source

Pharmacogenomic profiling of the efficacy of gemcitabine monotherapy in metastatic pancreatic cancer: Subgroup analysis of the GENESECT study

British Journal of Clinical Pharmacology, EarlyView.
Aim In the GENESECT study, no significant gemcitabine (GEM) metabolism‐related germline genetic polymorphisms (GPs) were identified because approximately 70% of patients received combination therapy with nab‐paclitaxel, which has metabolic pathways different from GEM.
Takashi Yokokawa, Daiki Tsuji, Masahiro Hatori, Kazuyoshi Kawakami, Masahiko Nakao, Takuya Yano, Yuichiro Arakawa, Keisuke Matsuo, Yasukata Ohashi, Masato Ozaka, Naoki Sasahira, Yasuhiko Sakata, Yuki Kogure, Shinya Tamaki, Atsushi Wada, Yusuke Taki, Wataru Suzuki, Kazuo Kobayashi, Hiroshi Ishii, Kunihiko Itoh, Masakazu Yamaguchi, Kenichi Suzuki   +21 more
wiley   +1 more source